Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Liso-cel for second-line R/R aggressive large B-cell NHL

Nilanjan Ghosh • 18 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel
TRANSCEND-PILOT-017006

Nilanjan Ghosh MD, PhD, of Levine Cancer Institute, Charlotte, NC, updates us on results of the TRANSCEND-PILOT-017006 study (NCT03483103) investigating lisocabtagene maraleucel (liso-cel), a CD19 directed CAR-T cell therapy, for the treatment of second-line, transplant-ineligible relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nilanjan Ghosh

Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
6:42
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
Nilanjan Ghosh • 10 Dec 2025
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL
2:31
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL
Nilanjan Ghosh • 10 Dec 2025
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
15:00
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
Nilanjan Ghosh • 27 Jun 2025
An overview of CAR T-cell therapies in the treatment of patients with MCL
6:46
An overview of CAR T-cell therapies in the treatment of patients with MCL
Nilanjan Ghosh • 26 Jun 2024

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Nilanjan Ghosh • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Nilanjan Ghosh • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Nilanjan Ghosh • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Nilanjan Ghosh • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals